Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Austin Wesevich, Daniel A. Goldstein, Koosha Paydary, Cody J. Peer, William D. Figg, Mark J. Ratain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer types. The doses of these drugs, though approved by the Food and Drug Administration (FDA), have never been optimised, likely leading to significantly higher doses than required for optimal efficacy. Dose optimisation would hypothetically decrease the risk, severity, and duration of immune-related adverse events, as well as provide an opportunity to reduce costs through interventional pharmacoeconomic strategies such as off-label dose reductions or less frequent dosing. We summarise existing evidence for ICI dose optimisation to advocate for the role of interventional pharmacoeconomics.

Original languageEnglish
Pages (from-to)1389-1396
Number of pages8
JournalBritish Journal of Cancer
Issue number9
StatePublished - 26 Oct 2023


FundersFunder number
National Cancer InstituteT32CA009566, T32GM007019
National Institute of General Medical Sciences


    Dive into the research topics of 'Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies'. Together they form a unique fingerprint.

    Cite this